Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck
Robert L. Ferris(University of Pittsburgh), Ezra E.W. Cohen(Moores Cancer Center), Raphaël Gottardo(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Antonio Jimeno(University of Colorado Cancer Center), Ammar Sukari(The Barbara Ann Karmanos Cancer Institute), Moon J. Fenton(University of Tennessee Health Science Center), Robert M. Hershberg(Hebrew University of Jerusalem), Nabil F. Saba(Emory University), Krzysztof Misiukiewicz(Mount Sinai Medical Center), Keisuke Shirai(National Institute of Advanced Industrial Science and Technology), Barbara J. Gitlitz(University of Southern California), Assuntina G. Sacco(University of California San Diego), Charles Schneider(University of Pennsylvania), Douglas R. Adkins(Washington University in St. Louis), Julie E. Bauman(George Washington University), Robert I. Haddad(Georgetown University), Daniel W. Bowles(University of Colorado Denver), James Kyle Bryan, Kristi L. Manjarrez, T. Nwizu(Cleveland Clinic), Gregory N. Dietsch, Prakash Neupane(University of Kansas Medical Center), John C. Morris(Alzheimer's Association), Michael K. Gibson(Vanderbilt University)
Cited by 111
Related Papers
Integrated analysis of multimodal single-cell data
|Cell|2021|16.2k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k